Sobi nets deal with Republic of Ireland to provide its therapies for haemophilia
February 7, 2018Republic of Ireland’s Health Service Executive (HSE) and Sobi have signed a supply deal to offer people with with haemophilia haemophilia treatments, extended half-life therapies.
A new contract for the supply of Elocta (efmoroctocog alfa), for the treatment of haemophilia A was signed in January 2018. It follows an earlier contract for the supply of Alprolix, for the treatment of haemophilia B. Both Elocta and Alprolix are extended half-life treatments approved for all age groups in the EU, noted Sobi.
Steve Bojakowski, Sobi’s Patient Access Lead for the UK and the Republic of Ireland, said: “With the outcome of the adjudication of both of these tenders, Sobi has demonstrated our desire to provide access to these innovative products in a very sustainable manner.”
The Republic of Ireland procurement team has adopted the World Federation of Hemophilia’s guidelines for national tenders for the purchase of clotting factor concentrates. Under the guidelines, the tender process for the Alprolix and Elocta contracts included doctors and patients in the product evaluation process.
